BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 9511063)

  • 1. A review of in-vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus.
    Low DE; Nadler HL
    J Antimicrob Chemother; 1997 May; 39 Suppl A():53-8. PubMed ID: 9511063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates.
    Sambatakou H; Giamarellos-Bourboulis EJ; Grecka P; Chryssouli Z; Giamarellou H
    J Antimicrob Chemother; 1998 Mar; 41(3):349-55. PubMed ID: 9578161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.
    Kang SL; Rybak MJ
    J Antimicrob Chemother; 1997 May; 39 Suppl A():33-9. PubMed ID: 9511060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro activity of quinupristin/dalfopristin and seven other antimicrobials against methicillin-susceptible and methicillin-resistant nosocomial Staphylococcus aureus bloodstream isolates.
    Nikolaidis P; Metallidis S; Katikaridou E; Chatzidimitriou M; Kollaras P; Tsona A; Koumentaki E; Tourkantonis A
    J Chemother; 2002 Dec; 14(6):544-6. PubMed ID: 12583543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of telithromycin, quinupristin/dalfopristin, linezolid and comparator antimicrobial agents against Staphylococcus aureus clinical isolates.
    Millán L; Cerdá P; Rubio MC; Goñi P; Canales M; Capilla S; Oca M; Gómez-Lus R
    J Chemother; 2004 Jun; 16(3):230-7. PubMed ID: 15330317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes.
    Baudoux P; Lemaire S; Denis O; Tulkens PM; Van Bambeke F; Glupczynski Y
    J Antimicrob Chemother; 2010 Jun; 65(6):1228-36. PubMed ID: 20378672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics.
    Zarrouk V; Bozdogan B; Leclercq R; Garry L; Feger C; Carbon C; Fantin B
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1244-8. PubMed ID: 11257041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative antimicrobial activity of RP 59,500 (quinupristin-dalfopristin), the first semisynthetic injectable streptgramin, against gram-positive cocci and other recent clinical pathogens].
    Nakashio S; Iwasawa H; Iino S; Shimada J
    Jpn J Antibiot; 1997 Oct; 50(10):844-53. PubMed ID: 9412874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [MIC and MBC of quinupristin/dalfopristin of erythromycin-resistant MRSA strains isolated from clinical specimens].
    Młynarczyk G; Młynarczyk A; Szymanek K; Bilewska A; Pupek J; Luczak M
    Med Dosw Mikrobiol; 2006; 58(3):199-205. PubMed ID: 17340994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
    Jones RN; Ballow CH; Biedenbach DJ; Deinhart JA; Schentag JJ
    Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro activity of quinupristin/dalfopristin, levofloxacin and moxifloxacin against fusidic acid and rifampicin-resistant strains of methicillin-resistant Staphylococcus aureus (MRSA) from Malaysian hospitals.
    Norazah A; Lim VK; Rohani MY; Kamel AG
    Med J Malaysia; 2005 Oct; 60(4):411-5. PubMed ID: 16570701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bactericidal activity of quinupristin-dalfopristin against Staphylococcus aureus: clindamycin susceptibility as a surrogate indicator.
    Fuchs PC; Barry AL; Brown SD
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2880-2. PubMed ID: 10991879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of methicillin-resistant Staphylococcus aureus clinical isolates to various antimicrobial agents. III. Novel, inducible resistance to macrolide-lincosamide-streptogramin B (MLS) antibiotics.
    Inouye Y; Morifuji K; Masumi N; Sugiyama M; Takesue Y; Kodama T; Yokoyama T
    Hiroshima J Med Sci; 1993 Sep; 42(3):101-7. PubMed ID: 8253604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of quinupristin-dalfopristin with eight other antibiotics as measured by time-kill studies with 10 strains of Staphylococcus aureus for which quinupristin-dalfopristin alone was not bactericidal.
    Fuchs PC; Barry AL; Brown SD
    Antimicrob Agents Chemother; 2001 Sep; 45(9):2662-5. PubMed ID: 11502549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates.
    Dowzicky M; Nadler HL; Feger C; Talbot G; Bompart F; Pease M
    Am J Med; 1998 May; 104(5A):34S-42S. PubMed ID: 9684656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500.
    Entenza JM; Drugeon H; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1419-24. PubMed ID: 7492078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the in-vitro activity of quinupristin/dalfopristin against intracellular pathogens and mycoplasmas.
    Bébéar C; Bouanchaud DH
    J Antimicrob Chemother; 1997 May; 39 Suppl A():59-62. PubMed ID: 9511064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of inducible clindamycin resistance in staphylococci: first results from Turkey.
    Azap OK; Arslan H; Timurkaynak F; Yapar G; Oruç E; Gagir U
    Clin Microbiol Infect; 2005 Jul; 11(7):582-4. PubMed ID: 15966979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antistaphylococcal activities of quinupristin/dalfopristin in vitro across platelet-fibrin matrices and in experimental endocarditis.
    Berthaud N; Huet Y; Diallo N; Desnottes JF
    J Antimicrob Chemother; 1997 May; 39 Suppl A():93-8. PubMed ID: 9511071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bactericidal activity of quinupristin-dalfopristin against strains of Staphylococcus aureus with the MLS(B) phenotype of resistance according to the erm gene type.
    Clarebout G; Nativelle E; Bozdogan B; Villers C; Leclercq R
    Int J Antimicrob Agents; 2004 Nov; 24(5):444-9. PubMed ID: 15519475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.